← Eichor
Study identifier: NCT05316805 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project

Condition: Atopic Dermatitis Eczema · Prurigo Nodularis  ·  Sponsor: Peking University First Hospital

PhaseN/A
Planned participants100000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Yang Wang, Doctor  ·  008613811232795  ·  yangwang_dr@bjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University First HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05316805